| . | Coadministration Group (RSVpreF + SIIV)/placebo (na = 703) . | Sequential Administration Group (Placebo + SIIV)/RSVpreF (na = 696) . |
|---|---|---|
| Age at vaccination, median (range), y | 70 (65–91) | 70 (65–88) |
| Age group at vaccination 1, n (%) | ||
| 65–74 y | 567 (80.7) | 559 (80.3) |
| ≥75 y | 136 (19.3) | 137 (19.7) |
| Sex, n (%) | ||
| Male | 305 (43.4) | 324 (46.6) |
| Female | 398 (56.6) | 372 (53.4) |
| Race, n (%) | ||
| White | 669 (95.2) | 665 (95.5) |
| Asian | 22 (3.1) | 21 (3.0) |
| American Indian or Alaska Native | 0 | 1 (0.1) |
| Native Hawaiian or Other Pacific Islander | 4 (0.6) | 3 (0.4) |
| Not reported | 2 (0.3) | 1 (0.1) |
| Unknown | 2 (0.3) | 4 (0.6) |
| Multiracial | 4 (0.6) | 1 (0.1) |
| Racial designation, n (%) | ||
| Indigenous Australianb | 3 (0.4) | 6 (0.9) |
| Otherc | 302 (43.0) | 281 (40.4) |
| Missing | 398 (56.6) | 409 (58.8) |
| Ethnicity, n (%) | ||
| Non-Hispanic/non-Latino | 652 (92.7) | 647 (93.0) |
| Hispanic/Latino | 5 (0.7) | 8 (1.1) |
| Not reported | 46 (6.5) | 41 (5.9) |
| Tobacco use, n (%) | ||
| Current | 30 (4.3) | 36 (5.2) |
| Former | 294 (41.8) | 270 (38.8) |
| Never | 379 (53.9) | 390 (56.0) |
| . | Coadministration Group (RSVpreF + SIIV)/placebo (na = 703) . | Sequential Administration Group (Placebo + SIIV)/RSVpreF (na = 696) . |
|---|---|---|
| Age at vaccination, median (range), y | 70 (65–91) | 70 (65–88) |
| Age group at vaccination 1, n (%) | ||
| 65–74 y | 567 (80.7) | 559 (80.3) |
| ≥75 y | 136 (19.3) | 137 (19.7) |
| Sex, n (%) | ||
| Male | 305 (43.4) | 324 (46.6) |
| Female | 398 (56.6) | 372 (53.4) |
| Race, n (%) | ||
| White | 669 (95.2) | 665 (95.5) |
| Asian | 22 (3.1) | 21 (3.0) |
| American Indian or Alaska Native | 0 | 1 (0.1) |
| Native Hawaiian or Other Pacific Islander | 4 (0.6) | 3 (0.4) |
| Not reported | 2 (0.3) | 1 (0.1) |
| Unknown | 2 (0.3) | 4 (0.6) |
| Multiracial | 4 (0.6) | 1 (0.1) |
| Racial designation, n (%) | ||
| Indigenous Australianb | 3 (0.4) | 6 (0.9) |
| Otherc | 302 (43.0) | 281 (40.4) |
| Missing | 398 (56.6) | 409 (58.8) |
| Ethnicity, n (%) | ||
| Non-Hispanic/non-Latino | 652 (92.7) | 647 (93.0) |
| Hispanic/Latino | 5 (0.7) | 8 (1.1) |
| Not reported | 46 (6.5) | 41 (5.9) |
| Tobacco use, n (%) | ||
| Current | 30 (4.3) | 36 (5.2) |
| Former | 294 (41.8) | 270 (38.8) |
| Never | 379 (53.9) | 390 (56.0) |
Data are for the safety population.
Abbreviations: RSVpreF, respiratory syncytial virus prefusion F protein-based vaccine; SIIV, seasonal inactivated influenza vaccine.
aNumber of participants in the specified vaccine group; these values were used as the denominators for the percentage calculations.
bDefined as a racial designation being Australian Aboriginal or Torres Strait Islander.
cDefined as a non-missing racial designation other than Australian Aboriginal or Torres Strait Islander and includes Indian Subcontinent Asian, Southeast Asian, Japanese, Chinese, Filipino, and other.
| . | Coadministration Group (RSVpreF + SIIV)/placebo (na = 703) . | Sequential Administration Group (Placebo + SIIV)/RSVpreF (na = 696) . |
|---|---|---|
| Age at vaccination, median (range), y | 70 (65–91) | 70 (65–88) |
| Age group at vaccination 1, n (%) | ||
| 65–74 y | 567 (80.7) | 559 (80.3) |
| ≥75 y | 136 (19.3) | 137 (19.7) |
| Sex, n (%) | ||
| Male | 305 (43.4) | 324 (46.6) |
| Female | 398 (56.6) | 372 (53.4) |
| Race, n (%) | ||
| White | 669 (95.2) | 665 (95.5) |
| Asian | 22 (3.1) | 21 (3.0) |
| American Indian or Alaska Native | 0 | 1 (0.1) |
| Native Hawaiian or Other Pacific Islander | 4 (0.6) | 3 (0.4) |
| Not reported | 2 (0.3) | 1 (0.1) |
| Unknown | 2 (0.3) | 4 (0.6) |
| Multiracial | 4 (0.6) | 1 (0.1) |
| Racial designation, n (%) | ||
| Indigenous Australianb | 3 (0.4) | 6 (0.9) |
| Otherc | 302 (43.0) | 281 (40.4) |
| Missing | 398 (56.6) | 409 (58.8) |
| Ethnicity, n (%) | ||
| Non-Hispanic/non-Latino | 652 (92.7) | 647 (93.0) |
| Hispanic/Latino | 5 (0.7) | 8 (1.1) |
| Not reported | 46 (6.5) | 41 (5.9) |
| Tobacco use, n (%) | ||
| Current | 30 (4.3) | 36 (5.2) |
| Former | 294 (41.8) | 270 (38.8) |
| Never | 379 (53.9) | 390 (56.0) |
| . | Coadministration Group (RSVpreF + SIIV)/placebo (na = 703) . | Sequential Administration Group (Placebo + SIIV)/RSVpreF (na = 696) . |
|---|---|---|
| Age at vaccination, median (range), y | 70 (65–91) | 70 (65–88) |
| Age group at vaccination 1, n (%) | ||
| 65–74 y | 567 (80.7) | 559 (80.3) |
| ≥75 y | 136 (19.3) | 137 (19.7) |
| Sex, n (%) | ||
| Male | 305 (43.4) | 324 (46.6) |
| Female | 398 (56.6) | 372 (53.4) |
| Race, n (%) | ||
| White | 669 (95.2) | 665 (95.5) |
| Asian | 22 (3.1) | 21 (3.0) |
| American Indian or Alaska Native | 0 | 1 (0.1) |
| Native Hawaiian or Other Pacific Islander | 4 (0.6) | 3 (0.4) |
| Not reported | 2 (0.3) | 1 (0.1) |
| Unknown | 2 (0.3) | 4 (0.6) |
| Multiracial | 4 (0.6) | 1 (0.1) |
| Racial designation, n (%) | ||
| Indigenous Australianb | 3 (0.4) | 6 (0.9) |
| Otherc | 302 (43.0) | 281 (40.4) |
| Missing | 398 (56.6) | 409 (58.8) |
| Ethnicity, n (%) | ||
| Non-Hispanic/non-Latino | 652 (92.7) | 647 (93.0) |
| Hispanic/Latino | 5 (0.7) | 8 (1.1) |
| Not reported | 46 (6.5) | 41 (5.9) |
| Tobacco use, n (%) | ||
| Current | 30 (4.3) | 36 (5.2) |
| Former | 294 (41.8) | 270 (38.8) |
| Never | 379 (53.9) | 390 (56.0) |
Data are for the safety population.
Abbreviations: RSVpreF, respiratory syncytial virus prefusion F protein-based vaccine; SIIV, seasonal inactivated influenza vaccine.
aNumber of participants in the specified vaccine group; these values were used as the denominators for the percentage calculations.
bDefined as a racial designation being Australian Aboriginal or Torres Strait Islander.
cDefined as a non-missing racial designation other than Australian Aboriginal or Torres Strait Islander and includes Indian Subcontinent Asian, Southeast Asian, Japanese, Chinese, Filipino, and other.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
